Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07652476 | Neurocognitive Assessment in Long-Term Survivors of Lymphoma(FIL_LymDeCo) | not yet recruiting | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02256137 | A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer | active not recruiting | — | 1,564 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03361020 | Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation | active not recruiting | — | 434 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03755804 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | active not recruiting | Phase 2 | 232 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03681561 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 54 | Veronika BachanovaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641010 | PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02917083 | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)(RELY-30) | recruiting | Phase 1 | 60 | Baylor College of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07222345 | Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma | recruiting | N/A | 20 | St. Jude Children's Research HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02663297 | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | active not recruiting | Phase 1 | 18 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT00107198 | Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease | completed | Phase 2 | 188 | Children's Oncology GroupNETWORK | 6 | Jun 5, 2026 | clinicaltrials |
| NCT05723055 | Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma(NAHL) | active not recruiting | Phase 2 | 9 | University of UtahOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01868451 | Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma | completed | N/A | 118 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06131801 | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | recruiting | — | 30 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05162976 | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | active not recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623850 | A Phase I Study of JLM019 Injection(JLM019) | recruiting | Phase 1 | 115 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04758650 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis(MITRAS) | terminated | Phase 2 | 29 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06822855 | Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma(LH_BIO) | recruiting | — | 755 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT04640779 | Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 22 | Mayo ClinicOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT05100056 | A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma(BV-MAZOVIA) | recruiting | — | 70 | TakedaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT00846742 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma | active not recruiting | Phase 2 | 88 | St. Jude Children's Research HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03434730 | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT01476410 | Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma | completed | Phase 2 | 49 | Northwestern UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06812858 | PD-1 Inhibitors Maintenance for cHL Post-autoHCT | recruiting | Phase 2 | 83 | St. Petersburg State Pavlov Medical UniversityOTHER | 2 | May 22, 2026 | clinicaltrials |
| NCT06098430 | Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) | recruiting | — | 100 | St. Jude Children's Research HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07575893 | CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma(REACH-CD30) | not yet recruiting | Phase 1 | 12 | New York Medical CollegeOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT01790152 | Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | recruiting | — | 420 | Children's Oncology GroupNETWORK | 4 | May 18, 2026 | clinicaltrials |
| NCT02362997 | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT02797470 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 11 | AIDS Malignancy ConsortiumNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT05355051 | A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05404945 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | active not recruiting | Phase 2 | 24 | University of VirginiaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT01703949 | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | active not recruiting | Phase 2 | 28 | University of WashingtonOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT01920932 | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma | active not recruiting | Phase 2 | 77 | St. Jude Children's Research HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03580564 | An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 109 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04636255 | Physical Capacity in Hodgkin Lymphoma Survivors | completed | N/A | 40 | University of Sao Paulo General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | suspended | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03057795 | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 62 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05949931 | Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma | recruiting | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT00131014 | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies | recruiting | — | 1,500 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 22, 2026source: clinicaltrials